Efficacy of elacytarabine as second-line therapy in patients with acute myeloid leukaemia

Trial Profile

Efficacy of elacytarabine as second-line therapy in patients with acute myeloid leukaemia

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2013

At a glance

  • Drugs Elacytarabine (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Aqualis
  • Most Recent Events

    • 29 Jul 2013 Status changed from recruiting to completed.
    • 07 Dec 2009 Results were presented at the 51st American Society of Hematology (ASH) Annual Meeting, according to a Clavis media release.
    • 04 Dec 2009 Results will be presented at the 51st Annual Meeting of the American Society of Hematology on 5 Dec 2009, according to a Clavis Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top